

Special Issue

Tumor Heterogeneity: Recent Trends and Current Issues

Message from the Guest Editors

Heterogeneity among cancer cells within one tumor and metastases thereof has gained increased attention particularly concerning the treatment of mamma carcinoma and gynecological malignancies such as ovarian cancer. Next to morphological and metabolic changes, different phenotypical profiles and altered genetic patterns, tumor cells exhibit diversification of motility, proliferation and metastatic potential. Hence, tumor heterogeneity plays a key role in cancer diagnosis, treatment choice, therapy response and patient outcome. Extremely heterogonous tumors are associated with aggressive behavior and treatment resistance. Deeper insight into mechanisms that drive tumor heterogeneity might help to identify novel treatment strategies and therapeutic targets. The Special Issue “Tumor heterogeneity” seeks to broaden the knowledge concerning crucial changes at various cellular and molecular levels that may influence carcinogenesis and prognosis. This Special Issue intends to publish original research articles, reviews and methodological papers.

Guest Editors

Prof. Dr. Bahriye Aktas

University of Leipzig, Medical Center, Dept. of Gynaecology, Leipzig, Germany

Dr. Ivonne Nel

Department of Gynecology, Medical Center, University of Leipzig, Leipzig, Germany

Deadline for manuscript submissions

closed (20 February 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/69490

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)